[{"orgOrder":0,"company":"Vedanta Biosciences","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"U.S.A","productType":"Microorganism","year":"2024","type":"Inapplicable","leadProduct":"VE303","moa":"Undisclosed","graph1":"Infections and Infectious Diseases","graph2":"Phase III","graph3":"Vedanta Biosciences","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Oral Capsule","sponsorNew":"Vedanta Biosciences \/ Inapplicable","highestDevelopmentStatusID":"10","companyTruncated":"Vedanta Biosciences \/ Inapplicable"},{"orgOrder":0,"company":"Vedanta Biosciences","sponsor":"Affiliates of Magnetar Capital","pharmaFlowCategory":"D","therapeuticArea":"Infections and Infectious Diseases","country":"U.S.A","productType":"Microorganism","year":"2021","type":"Series D Financing","leadProduct":"VE303","moa":"Undisclosed","graph1":"Infections and Infectious Diseases","graph2":"Phase III","graph3":"Vedanta Biosciences","amount2":0.070000000000000007,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Infectious Diseases","amount2New":0.070000000000000007,"dosageForm":"Oral Capsule","sponsorNew":"Vedanta Biosciences \/ Affiliates of Magnetar Capital","highestDevelopmentStatusID":"10","companyTruncated":"Vedanta Biosciences \/ Affiliates of Magnetar Capital"},{"orgOrder":0,"company":"Vedanta Biosciences","sponsor":"AXA IM Alts","pharmaFlowCategory":"D","therapeuticArea":"Infections and Infectious Diseases","country":"U.S.A","productType":"Microorganism","year":"2023","type":"Financing","leadProduct":"VE303","moa":"Undisclosed","graph1":"Infections and Infectious Diseases","graph2":"Phase III","graph3":"Vedanta Biosciences","amount2":0.11,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Infectious Diseases","amount2New":0.11,"dosageForm":"Oral Capsule","sponsorNew":"Vedanta Biosciences \/ AXA IM Alts","highestDevelopmentStatusID":"10","companyTruncated":"Vedanta Biosciences \/ AXA IM Alts"},{"orgOrder":0,"company":"Vedanta Biosciences","sponsor":"BARDA","pharmaFlowCategory":"D","therapeuticArea":"Infections and Infectious Diseases","country":"U.S.A","productType":"Microorganism","year":"2020","type":"Funding","leadProduct":"VE303","moa":"Undisclosed","graph1":"Infections and Infectious Diseases","graph2":"Phase III","graph3":"Vedanta Biosciences","amount2":0.080000000000000002,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Infectious Diseases","amount2New":0.080000000000000002,"dosageForm":"Oral Capsule","sponsorNew":"Vedanta Biosciences \/ BARDA","highestDevelopmentStatusID":"10","companyTruncated":"Vedanta Biosciences \/ BARDA"},{"orgOrder":0,"company":"Vedanta Biosciences","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"U.S.A","productType":"Microorganism","year":"2022","type":"Inapplicable","leadProduct":"VE303","moa":"Undisclosed","graph1":"Infections and Infectious Diseases","graph2":"Phase III","graph3":"Vedanta Biosciences","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Oral Capsule","sponsorNew":"Vedanta Biosciences \/ Inapplicable","highestDevelopmentStatusID":"10","companyTruncated":"Vedanta Biosciences \/ Inapplicable"},{"orgOrder":0,"company":"Vedanta Biosciences","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"U.S.A","productType":"Microorganism","year":"2023","type":"Inapplicable","leadProduct":"VE303","moa":"Undisclosed","graph1":"Infections and Infectious Diseases","graph2":"Phase III","graph3":"Vedanta Biosciences","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Oral Capsule","sponsorNew":"Vedanta Biosciences \/ Inapplicable","highestDevelopmentStatusID":"10","companyTruncated":"Vedanta Biosciences \/ Inapplicable"},{"orgOrder":0,"company":"Vedanta Biosciences","sponsor":"PureTech Health","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"U.S.A","productType":"Microorganism","year":"2022","type":"Inapplicable","leadProduct":"VE303","moa":"Undisclosed","graph1":"Infections and Infectious Diseases","graph2":"Phase III","graph3":"Vedanta Biosciences","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Oral Capsule","sponsorNew":"Vedanta Biosciences \/ PureTech Health","highestDevelopmentStatusID":"10","companyTruncated":"Vedanta Biosciences \/ PureTech Health"},{"orgOrder":0,"company":"Vedanta Biosciences","sponsor":"PureTech Health","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"U.S.A","productType":"Microorganism","year":"2022","type":"Inapplicable","leadProduct":"VE303","moa":"Undisclosed","graph1":"Infections and Infectious Diseases","graph2":"Phase III","graph3":"Vedanta Biosciences","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Oral Capsule","sponsorNew":"Vedanta Biosciences \/ PureTech Health","highestDevelopmentStatusID":"10","companyTruncated":"Vedanta Biosciences \/ PureTech Health"},{"orgOrder":0,"company":"Vedanta Biosciences","sponsor":"PureTech Health","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"U.S.A","productType":"Probiotic","year":"2023","type":"Inapplicable","leadProduct":"VE202","moa":"||Undisclosed","graph1":"Immunology","graph2":"Phase II","graph3":"Vedanta Biosciences","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Oral","sponsorNew":"Vedanta Biosciences \/ Vedanta Biosciences","highestDevelopmentStatusID":"8","companyTruncated":"Vedanta Biosciences \/ Vedanta Biosciences"},{"orgOrder":0,"company":"Vedanta Biosciences","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Gastroenterology","country":"U.S.A","productType":"Probiotic","year":"2021","type":"Inapplicable","leadProduct":"VE202","moa":"Undisclosed","graph1":"Gastroenterology","graph2":"Phase I","graph3":"Vedanta Biosciences","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Gastroenterology","amount2New":0,"dosageForm":"Oral","sponsorNew":"Vedanta Biosciences \/ Inapplicable","highestDevelopmentStatusID":"6","companyTruncated":"Vedanta Biosciences \/ Inapplicable"},{"orgOrder":0,"company":"Vedanta Biosciences","sponsor":"JSR Life Sciences","pharmaFlowCategory":"D","therapeuticArea":"Gastroenterology","country":"U.S.A","productType":"Probiotic","year":"2020","type":"Series C Financing","leadProduct":"VE202","moa":"Undisclosed","graph1":"Gastroenterology","graph2":"Phase I","graph3":"Vedanta Biosciences","amount2":0.070000000000000007,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Gastroenterology","amount2New":0.070000000000000007,"dosageForm":"Oral","sponsorNew":"Vedanta Biosciences \/ JSR Life Sciences","highestDevelopmentStatusID":"6","companyTruncated":"Vedanta Biosciences \/ JSR Life Sciences"},{"orgOrder":0,"company":"Vedanta Biosciences","sponsor":"Pfizer Inc","pharmaFlowCategory":"D","therapeuticArea":"Gastroenterology","country":"U.S.A","productType":"Probiotic","year":"2021","type":"Financing","leadProduct":"VE202","moa":"Undisclosed","graph1":"Gastroenterology","graph2":"Phase I","graph3":"Vedanta Biosciences","amount2":0.029999999999999999,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Gastroenterology","amount2New":0.029999999999999999,"dosageForm":"Oral","sponsorNew":"Vedanta Biosciences \/ Pfizer Inc","highestDevelopmentStatusID":"6","companyTruncated":"Vedanta Biosciences \/ Pfizer Inc"},{"orgOrder":0,"company":"Vedanta Biosciences","sponsor":"PureTech Health","pharmaFlowCategory":"DU","therapeuticArea":"Gastroenterology","country":"U.S.A","productType":"Probiotic","year":"2020","type":"Inapplicable","leadProduct":"VE202","moa":"Undisclosed","graph1":"Gastroenterology","graph2":"Phase I","graph3":"Vedanta Biosciences","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Gastroenterology","amount2New":0,"dosageForm":"Oral","sponsorNew":"Vedanta Biosciences \/ PureTech Health","highestDevelopmentStatusID":"6","companyTruncated":"Vedanta Biosciences \/ PureTech Health"},{"orgOrder":0,"company":"Vedanta Biosciences","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"U.S.A","productType":"Microorganism","year":"2024","type":"Inapplicable","leadProduct":"VE303","moa":"Undisclosed","graph1":"Infections and Infectious Diseases","graph2":"Phase III","graph3":"Vedanta Biosciences","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Vedanta Biosciences \/ Inapplicable","highestDevelopmentStatusID":"10","companyTruncated":"Vedanta Biosciences \/ Inapplicable"},{"orgOrder":0,"company":"Vedanta Biosciences","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"U.S.A","productType":"Probiotic","year":"2022","type":"Inapplicable","leadProduct":"VE202","moa":"Undisclosed","graph1":"Immunology","graph2":"Phase II","graph3":"Vedanta Biosciences","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Vedanta Biosciences \/ Inapplicable","highestDevelopmentStatusID":"8","companyTruncated":"Vedanta Biosciences \/ Inapplicable"},{"orgOrder":0,"company":"Vedanta Biosciences","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Undisclosed","country":"U.S.A","productType":"Microorganism","year":"2020","type":"Inapplicable","leadProduct":"VE303","moa":"Undisclosed","graph1":"Undisclosed","graph2":"Phase I","graph3":"Vedanta Biosciences","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Vedanta Biosciences \/ Inapplicable","highestDevelopmentStatusID":"6","companyTruncated":"Vedanta Biosciences \/ Inapplicable"}]

Find Clinical Drug Pipeline Developments & Deals by Vedanta Biosciences

Menu
Xls
Filters Filter
×
FILTER:
filter
Company Name
    filter

    Year

      filter

      DEALS // DEV.

        filter

        Country

          filter
          Sponsor
            filter

            Therapeutic Area

              filter

              Study Phase

                filter

                Deal Type

                  filter

                  Product Type

                    filter

                    Dosage Form

                      filter

                      Lead Product

                        filter

                        Target

                          Loading...

                          Therapeutic Area by Lead Product

                          Study Phase by Lead Product

                          Company by Lead Product

                          Top Deals by Deal Size (USD bn)

                          01

                          ChemOutsourcing
                          Not Confirmed
                          ChemOutsourcing
                          Not Confirmed

                          Details : VE303 is a potential first-in-class live biotherapeutic product candidate consisting of a defined bacterial consortium designed for the prevention of recurrent Clostridioides difficile infection.

                          Product Name : Undisclosed

                          Product Type : Microorganism

                          Upfront Cash : Inapplicable

                          May 21, 2024

                          Lead Product(s) : VE303

                          Therapeutic Area : Infections and Infectious Diseases

                          Highest Development Status : Phase III

                          Sponsor : Inapplicable

                          Deal Size : Inapplicable

                          Deal Type : Inapplicable

                          blank

                          02

                          ChemOutsourcing
                          Not Confirmed
                          ChemOutsourcing
                          Not Confirmed

                          Details : Undisclosed

                          Product Name : Undisclosed

                          Product Type : Microorganism

                          Upfront Cash : Inapplicable

                          February 01, 2024

                          Lead Product(s) : VE303

                          Therapeutic Area : Infections and Infectious Diseases

                          Highest Development Status : Phase III

                          Sponsor : Inapplicable

                          Deal Size : Inapplicable

                          Deal Type : Inapplicable

                          blank

                          03

                          ChemOutsourcing
                          Not Confirmed
                          ChemOutsourcing
                          Not Confirmed

                          Details : VE303 is a defined bacterial consortium therapeutic candidate designed for the prevention of recurrent Clostridioides difficile infection (rCDI). It was granted orphan drug designation and fast track designation.

                          Product Name : Undisclosed

                          Product Type : Microorganism

                          Upfront Cash : Inapplicable

                          August 05, 2023

                          Lead Product(s) : VE303

                          Therapeutic Area : Infections and Infectious Diseases

                          Highest Development Status : Phase II

                          Sponsor : Inapplicable

                          Deal Size : Inapplicable

                          Deal Type : Inapplicable

                          blank

                          04

                          ChemOutsourcing
                          Not Confirmed
                          ChemOutsourcing
                          Not Confirmed

                          Details : The financing will be used to support pivotal-stage development of its lead candidate, VE303, for the prevention of recurrent Clostridioides difficile infection (CDI), and a Phase 2 study of VE202 for ulcerative colitis, among other development activitie...

                          Product Name : Undisclosed

                          Product Type : Microorganism

                          Upfront Cash : Undisclosed

                          April 25, 2023

                          Lead Product(s) : VE303

                          Therapeutic Area : Infections and Infectious Diseases

                          Highest Development Status : Phase II

                          Sponsor : AXA IM Alts

                          Deal Size : $106.5 million

                          Deal Type : Financing

                          blank

                          05

                          ChemOutsourcing
                          Not Confirmed
                          ChemOutsourcing
                          Not Confirmed

                          Details : VE202 is a first-in-class, orally administered, investigational live biotherapeutic product (LBP) consortium consisting of 16 strains of bacteria, which is investigated for the treatment of ulcerative colitis.

                          Product Name : Undisclosed

                          Product Type : Probiotic

                          Upfront Cash : Inapplicable

                          April 10, 2023

                          Lead Product(s) : VE202,Vancomycin Hydrochloride

                          Therapeutic Area : Immunology

                          Highest Development Status : Phase II

                          Recipient : PureTech Health

                          Deal Size : Inapplicable

                          Deal Type : Inapplicable

                          blank

                          06

                          ChemOutsourcing
                          Not Confirmed
                          ChemOutsourcing
                          Not Confirmed

                          Details : VE303 is an orally administered, rationally-defined bacterial consortium candidate being developed for high-risk Clostridioides difficile (CDI) infection.

                          Product Name : Undisclosed

                          Product Type : Microorganism

                          Upfront Cash : Inapplicable

                          June 28, 2022

                          Lead Product(s) : VE303

                          Therapeutic Area : Infections and Infectious Diseases

                          Highest Development Status : Phase II

                          Sponsor : PureTech Health

                          Deal Size : Inapplicable

                          Deal Type : Inapplicable

                          blank

                          07

                          ChemOutsourcing
                          Not Confirmed
                          ChemOutsourcing
                          Not Confirmed

                          Details : Data presentations include review of the VE303 Phase 2 CONSORTIUM study, in which VE303 was well tolerated and highly active at preventing Clostridioides difficile infection recurrence in subjects at high risk of recurrence.

                          Product Name : Undisclosed

                          Product Type : Microorganism

                          Upfront Cash : Inapplicable

                          May 24, 2022

                          Lead Product(s) : VE303

                          Therapeutic Area : Infections and Infectious Diseases

                          Highest Development Status : Phase II

                          Sponsor : Inapplicable

                          Deal Size : Inapplicable

                          Deal Type : Inapplicable

                          blank

                          08

                          ChemOutsourcing
                          Not Confirmed
                          ChemOutsourcing
                          Not Confirmed

                          Details : Undisclosed

                          Product Name : Undisclosed

                          Product Type : Probiotic

                          Upfront Cash : Inapplicable

                          May 12, 2022

                          Lead Product(s) : VE202

                          Therapeutic Area : Immunology

                          Highest Development Status : Phase II

                          Sponsor : Inapplicable

                          Deal Size : Inapplicable

                          Deal Type : Inapplicable

                          blank

                          09

                          ChemOutsourcing
                          Not Confirmed
                          ChemOutsourcing
                          Not Confirmed

                          Details : Vedanta reported positive topline results from Phase 2 CONSORTIUM trial, in which VE303 was associated with a 31.7% absolute risk reduction in rate of recurrence when compared with placebo, representing a greater than 80% reduction in odds of a CDI recur...

                          Product Name : Undisclosed

                          Product Type : Microorganism

                          Upfront Cash : Inapplicable

                          April 13, 2022

                          Lead Product(s) : VE303

                          Therapeutic Area : Infections and Infectious Diseases

                          Highest Development Status : Phase II

                          Sponsor : PureTech Health

                          Deal Size : Inapplicable

                          Deal Type : Inapplicable

                          blank

                          10

                          ChemOutsourcing
                          Not Confirmed
                          ChemOutsourcing
                          Not Confirmed

                          Details : Vedanta intends to use the proceeds to fund a Phase 2 study of VE202 in inflammatory bowel disease (IBD), which it plans to initiate in 2021.

                          Product Name : Undisclosed

                          Product Type : Probiotic

                          Upfront Cash : Undisclosed

                          December 01, 2021

                          Lead Product(s) : VE202

                          Therapeutic Area : Gastroenterology

                          Highest Development Status : Phase I

                          Sponsor : Pfizer Inc

                          Deal Size : $25.0 million

                          Deal Type : Financing

                          blank